Korea UCB Co Ltd - Company Review
Korea UCB Co Ltd - Company ReviewSummary
Korea UCB Co Ltd (Korea UCB), a subsidiary of UCB SA is a biopharmaceutical company that offers research and developments in central nervous system disorders, respiratory diseases, and immune areas. The company’s products include kepeura, bimpaet, avonex, palm fira, dera tekpi, zyrtec, and others. Its services include clinical trials, research and development, drug development and allergy therapeutic services. The company offers treatment in the areas of systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, coronary artery disease, and other diseases. Korea UCB is headquartered in Seoul, South Korea.
This comprehensive company report of Korea UCB Co Ltd provides you with company's businesses and operations information.
The profile contains critical company information including,
- Company Overview - A detailed description of the company's operations and business divisions.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.
Our valuable research and consulting solutions ensure you stay at the forefront of the industry by integrating accurate market forecasts and healthcare analytics on the latest trends and developments. Among other benefits, our informed healthcare industry perspectives have assisted businesses based across the pharmaceuticals, biotechnology and medical equipment markets in making strategic decisions that have increased the value of their products and services.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.